

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Balance Sheet

As At	Note No	31-Mar-14		31-Mar-13	
		CAD	INR'000	CAD	INR'000
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share Capital	1	50,000	2,452	50,000	2,452
Reserves & Surplus	2	60,429	3,540	52,780	3,040
		110,429	5,992	102,780	5,492
Current liabilities					
Trade Payables	3	43,877	2,381	18,203	973
Other Current liabilities	4	248,532	13,488	118,896	6,354
Short-term provisions	5	2,847	155	5,991	320
		295,256	16,024	143,090	7,647
	Total	405,685	22,016	245,870	13,139
II. ASSETS					
Current Assets					
Trade receivables	6	164,313	8,917	123,395	6,594
Cash & bank balances	7	241,372	13,099	122,475	6,545
		405,685	22,016	245,870	13,139
	Total	405,685	22,016	245,870	13,139
<p>RAJNEESH GUPTA Head - Accounts</p> <p>Place : Noida Date: 23 May 2014</p>					

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Statement of Profit and Loss

For the year ended,	Note No	31-Mar-14		31-Mar-13	
		CAD	INR'000	CAD	INR'000
REVENUE					
Revenue from Operations	8	74,800	4,290	729,717	39,660
Total Revenue		74,800	4,290	729,717	39,660
EXPENSES					
Employee benefits expenses	9	-	-	539,505	29,322
Finance costs	10	148	8	-	-
Other expenses	11	62,108	3,583	164,534	8,942
Total Expenses		62,256	3,591	704,039	38,264
Profit Before exceptional and extraordinary items and tax		12,544	699	25,678	1,396
Exceptional Items	12	1,960	115	3,405	185
Profit Before Tax		10,584	584	22,273	1,211
Tax expenses:					
- Current Tax		2,934	165	7,748	421
		2,934	165	7,748	421
Profit after Tax		7,650	419	14,525	790

RAJNEESH GUPTA
Head - Accounts

Place : Noida
Date: 23 May 2014

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC
CASH FLOW STATEMENT

For the year ended,	31-Mar-14		31-Mar-13	
	CAD	(INR' 000)	CAD	(INR' 000)
A. Cash Flow arising from Operating Activities :				
Net profit before tax	10,584	584	22,273	1,211
Adjustments for:				
Finance costs	148	8		
	148	8	-	-
Operating Profit before Working Capital Changes	10,732	592	22,273	1,211
Adjustments for :				
(Increase)/Decrease in Trade and Other Receivables-Non Current	(40,918)	(2,347)	(67,652)	(3,677)
(Increase)/Decrease in Trade and Other Receivables-Current	155,309	8,910	43,176	2,346
Increase/(Decrease) in Current Liabilities & Provisions-Current				
Cash generated from Operations	125,123	7,155	(2,203)	(120)
Interest Paid				
Direct Taxes Paid (net of refunds)	(6,078)	(349)	(7,748)	(421)
Interest Income Received				
Net Cash Inflow/(Outflow) in course of Operating Activities	119,045	6,806	(9,951)	(541)
B. Cash Flow arising from Financing Activities :				
Finance Cost paid	(148)	(8)	-	-
Net Cash Inflow/(Outflow) in course of Financing Activities	(148)	(8)	-	-
C. Foreign Currency Translation Difference arising on Consolidation		(244)		327
Net Increase in Cash & Cash equivalents (A+B+C)	118,897	6,554	(9,951)	(214)
Add: Cash & Cash Equivalents at the beginning of Year	122,475	6,545	132,426	6,759
Adjustment: Cash & Cash Equivalents on account of scheme of Amalgamation & Demerger				
Cash & Cash Equivalents at the close of the Year	241,372	13,099	122,475	6,545

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

2) Amounts in brackets are for cash outflows

3) Previous Year's figures have been regrouped/rearranged wherever found necessary to confirm to this year's classification

RAJNEESH GUPTA

Head - Accounts

Place : Noida

Date: 23 May 2014

JUBILANT DRUG DISCOVERY & DEVELOPMENT SERVICES INC

Notes to the Accounts as at	31-Mar-14		31-Mar-13	
	CAD	INR'000	CAD	INR'000
1 SHARE CAPITAL				
Issued & Subscribed				
50,000 Equity Shares of CAD 1 Each	50,000	2,452	50,000	2,452
	50,000	2,452	50,000	2,452
Paid up				
50,000 Equity Shares of CAD 1 Each	50,000	2,452	50,000	2,452
	50,000	2,452	50,000	2,452

1) The Company has only class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no preferential liability exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

3) The details of shares held by holding / ultimate holding company and / or their subsidiaries / associates: -

Name of the shareholder	31-Mar-14		31-Mar-13	
	No. of shares	% held	No. of shares	% held
'Jubilant Innovation Pte Limited, Singapore - The Holding Company	50,000	100%	50,000	100%

4) The details of shareholders holding more than 5% shares as at 31st March,2014 is set out below:

Name of the shareholder	No of shares	% held as at 31st March,2014	No of shares	% held as at 31st March,2013
Jubilant Innovation Pte Limited, Singapore	50,000	100%	50,000	100%

6) The reconciliation of the number of shares outstanding as at 31st March,2014 is set out below:

Particulars	As at 31st March,2014		As at 31st March 2013	
	No.	INR'000	No.	INR'000
Numbers of shares at the beginning	50,000	2,452	50,000	2,452
Numbers of shares at the end	50,000	2,452	50,000	2,452

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Notes to the Accounts as at	31-Mar-14		31-Mar-13	
	CAD	INR'000	CAD	INR'000
2 RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
As per last Balance Sheet		404		207
Addition/(deduction) during the year		82		197
	-	486	-	404
Surplus as per P&L Account				
As per last Balance Sheet	52,779	2,635	38,255	1,846
Add: Net Profit after tax transferred from Statement of Profit and Loss	7,650	419	14,525	790
Less: Adjustments on account of Scheme of Amalgamation & Demerger				
	60,429	3,054	52,780	2,636
	60,429	3,540	52,780	3,040
CURRENT LIABILITIES				
3 TRADE PAYABLES				
Trade Payables - Others	43,877	2,381	18,203	973
	43,877	2,381	18,203	973
4 OTHER CURRENT LIABILITIES				
Income received in Advance/Unearned Revenue	217,189	11,787	99,700	5,328
Other payables	31,343	1,701	19,196	1,026
	248,532	13,488	118,896	6,354
5 SHORT-TERM PROVISIONS				
Income Tax & Wealth Tax	2,847	155	5,991	320
	2,847	155	5,991	320

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Notes to the Accounts as at	31-Mar-14		31-Mar-13	
	CAD	INR'000	CAD	INR'000
CURRENT ASSETS				
6 TRADE RECEIVABLES				
Unsecured,considered good unless stated otherwise Outstanding for period exceeding six months from the date they are due for payment				
Unsecured,considered good	-	-	-	-
Doubtful	-	-	-	-
Provision for doubtful receivables	-	-	-	-
Other receivables				
Unsecured,considered good	164,313	8,917	123,395	6,594
Doubtful	-	-	-	-
Provision for doubtful receivables	164,313	8,917	123,395	6,594
	164,313	8,917	123,395	6,594
	164,313	8,917	123,395	6,594
7 CASH AND BANK BALANCES				
Cash and cash equivalents				
Balances with banks:				
- On Current Accounts	241,372	13,099	122,475	6,545
	241,372	13,099	122,475	6,545

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Notes to accounts for the year ended,	31-Mar-14		31-Mar-13	
	CAD	INR'000	CAD	INR'000
8 REVENUE FROM OPERATIONS				
Sales of services	74,800	4,290	729,717	39,660
Revenue from Operations(net)	74,800	4,290	729,717	39,660
9 EMPLOYEE BENEFITS EXPENSES				
Salaries, Wages, Bonus, Gratuity & Allowances	-	-	525,643	28,569
Staff Welfare Expenses	-	-	13,862	753
	-	-	539,505	29,322
10 OTHER EXPENSES				
Rates & Taxes	5,138	294	-	-
Advertisement, Publicity & Sales Promotion	-	-	123	7
Traveling & Other Incidental Expenses	-	-	83,186	4,521
Office Maintenance	-	-	192	10
Vehicle Running & Maintenance	-	-	-	-
Communication Expenses	-	-	14,577	792
Legal , Professional & Consultancy Charges	56,174	3,243	62,945	3,421
Miscellaneous Expenses	-	-	51	3
Bank charges	796	46	3,460	188
	62,108	3,583	164,534	8,942
11 FINANCE COST				
Other Borrowings Cost	148	8	-	-
	148	8	-	-
12 Exceptional items				
Foreign Exchange Gain/Loss	1,960	115	3,405	185
	1,960	115	3,405	185